Prothena(PRTA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2024 Financial Results and Business Highlights • Net cash used in operating and investing activities was $102.5 million and$102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million • PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzh ...